Recordati completes Turkish buy, more acquisitions to come
Recordati of Italy has completed the acquisition of Turkish pharmaceutical firm Yeni Ilac for 48 million euros.
Read MoreAuthor: Kevin Grogan
AstraZeneca links up with Biocompatibles for GLP-1 drug
AstraZeneca has signed an agreement to develop a diabetes drug with the UK’s Biocompatibles which could change the face of the Farnham, Surrey-based firm, which is best known for its devices.
Read MoreAntisoma looks for partner for US-approved oral fludarabine
Antisoma of the UK is celebrating the news that the US Food and Drug Administration has approved its tablet formulation of fludarabine as a second-line treatment for chronic lymphocytic leukaemia.
Read MoreGSK aptamer deal with Archemix could be worth $1.4 billion
Another day and yet another deal for GlaxoSmithKline which has signed a pact with the USA’s Archemix to develop aptamer therapeutics to treat inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.
Read MoreTakeda begins Phase III study of obesity drug cetilistat
Takeda Pharmaceutical Co says it has started a Phase III clinical study in Japan of cetilistat, a treatment for obesity and related diseases which is licensed from the UK’s Alizyme.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
